Observing corneal abrasions in patients with Dystrophic Epidermolysis Bullosa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the natural history of corneal abrasions in patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be monitored through remote weekly symptom diaries and monthly questionnaires to gather data on the symptoms, frequency, and duration of corneal abrasions. The study does not involve any interventions but focuses on understanding the condition's progression over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subject or their respective legal guardian must have read, understood, and signed an Institutional Review Board (IRB) approved Informed Consent/Assent Form and must be able to and willing to follow study procedures and instructions.
2. Age 6 months or older at time of Informed Consent/Assent.
3. Prior genetic diagnosis of DEB due to mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

Where it's running

• Krystal Biotech
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: David Chien, MD
• Email: dchien@krystalbio.com
• Phone: 412-586-5830

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gene-modified autologous skin graft (GMEB-SASS) for RDEB

  This trial will try a gene-modified skin graft grown from a patient's own cells to help wounds heal in people with recessive dystrophic epidermolysis bullosa (RDEB).

  Recruiting Phase 1/2 CHU de Quebec-Universite Laval · Toronto, Ontario · NCT07193134

• Understanding characteristics of patients with recessive dystrophic epidermolysis bullosa

  This study looks at people with recessive dystrophic epidermolysis bullosa to gather information that could help find new treatments for their skin condition.

  Recruiting Stanford University · Stanford, California · NCT01019148

• Long-Term Safety Follow-Up After pz-cel for RDEB

  This study follows people with RDEB who were treated with pz-cel to see how safe it is over up to 15 years and whether their wounds stay healed.

  Recruiting at 4 sites Abeona Therapeutics, Inc · Palo Alto, California and 3 other locations · NCT07700966

• KB803 eye drops versus placebo for people with dystrophic epidermolysis bullosa

  This trial tests whether KB803 eye drops, given three times a week, can reduce recurrent corneal abrasions in children and adults with dystrophic epidermolysis bullosa.

  Recruiting at 5 sites Phase 3 Krystal Biotech, Inc. · Rancho Santa Margarita, California and 4 other locations · NCT07016750

• Using IV immunoglobulin to lower collagen VII antibodies in dystrophic epidermolysis bullosa

  This trial tests whether IV immunoglobulin given to people with recessive dystrophic epidermolysis bullosa who are on VYJUVEK helps wounds heal faster and lowers collagen VII and HSV‑1 antibody levels.

  Recruiting Phase 1/2 Stanford University · Redwood City, California · NCT06834035

• Long-term follow-up for gene therapy in skin conditions

  This study is checking the long-term safety of a gene therapy for people with a skin condition called dystrophic epidermolysis bullosa who have already received the treatment.

  Recruiting at 3 sites Krystal Biotech, Inc. · Rancho Santa Margarita, California and 2 other locations · NCT04917887

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.